drugset / Trial / NCT04189211
A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
An Open-Label, Dose Escalation Phase I Clinical Trial on Safety, Tolerability and Pharmacokinetics of BAT8001 for Injection in Patients with HER2-Positive Solid Tumors (breast cancer or gastric cancer)。
Timeline
- Start
- 2017-03-07
- Primary completion
- 2019-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAT8001 | Monoclonal antibody | 1.2 mg/kg | Intravenous |
| Subject | BAT8001 | Monoclonal antibody | 2.4 mg/kg | Intravenous |
| Subject | BAT8001 | Monoclonal antibody | 3.6 mg/kg | Intravenous |
| Subject | BAT8001 | Monoclonal antibody | 4.8 mg/kg | Intravenous |
| Subject | BAT8001 | Monoclonal antibody | 6 mg/kg | Intravenous |